Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (181-190 of 209) with videos related to

Pageof 21
Sort By:
Dermatology and Therapy|November 22, 2019
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of ExposureApril Armstrong, Carle Paul, Luis Puig, et al.
Dermatology and Therapy|June 28, 2021
Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe ADRebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
Dermatology and Therapy|December 31, 2020
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe ADRebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
The British Journal of Dermatology|March 21, 2023
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Diamant Thaçi, Kim A Papp, et al.
Journal of the American Academy of Dermatology|August 8, 2023
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-upKim A Papp, Andrew Blauvelt, Lluís Puig, et al.
Dermatology and Therapy|March 28, 2025
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability StudyDavid M Pariser, Mark G Lebwohl, Janusz Jaworski, et al.
The New England Journal of Medicine|July 16, 2020
Trial of Roflumilast Cream for Chronic Plaque PsoriasisMark G Lebwohl, Kim A Papp, Linda Stein Gold, et al.
The British Journal of Dermatology|March 9, 2023
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trialZoe D Draelos, David N Adam, H Chih-Ho Hong, et al.
American Journal of Clinical Dermatology|November 12, 2022
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b TrialLinda Stein Gold, Javier Alonso-Llamazares, Zoe D Draelos, et al.
The New England Journal of Medicine|November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and AdolescentsRobert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
Pageof 21

Showing results (181-190 of 209) with videos related to

Sort By:
Pageof 21
Dermatology and Therapy|November 22, 2019
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of ExposureApril Armstrong, Carle Paul, Luis Puig, et al.
Dermatology and Therapy|June 28, 2021
Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe ADRebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
Dermatology and Therapy|December 31, 2020
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe ADRebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
The British Journal of Dermatology|March 21, 2023
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Diamant Thaçi, Kim A Papp, et al.
Journal of the American Academy of Dermatology|August 8, 2023
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-upKim A Papp, Andrew Blauvelt, Lluís Puig, et al.
Dermatology and Therapy|March 28, 2025
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability StudyDavid M Pariser, Mark G Lebwohl, Janusz Jaworski, et al.
The New England Journal of Medicine|July 16, 2020
Trial of Roflumilast Cream for Chronic Plaque PsoriasisMark G Lebwohl, Kim A Papp, Linda Stein Gold, et al.
The British Journal of Dermatology|March 9, 2023
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trialZoe D Draelos, David N Adam, H Chih-Ho Hong, et al.
American Journal of Clinical Dermatology|November 12, 2022
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b TrialLinda Stein Gold, Javier Alonso-Llamazares, Zoe D Draelos, et al.
The New England Journal of Medicine|November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and AdolescentsRobert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
Pageof 21